Development and Validation of a Prognostic Molecular Phenotype and Clinical Characterization in Grade III Diffuse Gliomas Treatment with Radio-Chemotherapy

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2025 Jan 13

PMID 39802957

Authors

Weiguo Gu

Jiaming Tang

Penghui Liu

Jinyu Gan

Jianfei Lai

Jinbiao Xu

Jianxiong Deng

Chaoxing Liu

Yuhua Wang

Guohua Zhang

Feng Yu

Chao Shi

Ke Fang

Feng Qiu

Affiliations

Soon will be listed here.

Abstract

Background: The relationship between molecular phenotype and prognosis in high-grade gliomas (WHO III and IV, HGG) treated with radiotherapy and chemotherapy is not fully understood and needs further exploration.

Methods: The HGG patients following surgery and treatment with radiotherapy and chemotherapy. Univariate and multivariate Cox analyses were used to assess the independent prognostic factors. The nomogram model was established, and its accuracy was determined via the calibration plots.

Results: A total of 215 and 88 patients had grade III glioma and grade IV glioma, respectively. Grade III oligodendroglioma (OG-G3) patients had the longest mPFS and mOS than other grade III pathology, while grade III astrocytoma (AA-G3) patients were close to IDH-1 wildtype glioblastoma (GBM) and had a poor prognosis. The IDH-1 mutant group had a better mPFS and mOS than the IDH-1 wildtype group in all grade III patients, OG-G3 and AA-G3 patients. Furthermore, 1p/19q co-deletion group had a longer mPFS and mOS than 1p/19q non-deletion group in all grade III patients. IDH-1 mutation and 1p/19q co-deletion patients had the best prognosis than other molecular types. Also, the MGMT methylation and IDH-1 mutation or 1p/19q co-deletion group had a longer mPFS and mOS than the MGMT unmethylation and IDH-1 wildtype or 1p/19q non-codeletion of grade III patients. In addition, the low Ki-67 expression group had a better prognosis than high Ki-67 expression group in grade III patients. Univariate and multivariate COX showed that 1p/19q co-deletion and MGMT methylation were the independent prognostic factors for mPFS and mOS. The calibration curve showed that the established nomogram could well predict the survival based on these covariates.

Conclusion: The AA-G3 with IDH-1 wildtype, MGMT unmethylation or 1p/19q non-codeletion patients was resistant to radiotherapy and chemotherapy, has a poor prognosis and needs a more active treatment.

References

Sun C, Xiao L, Zhao Y, Shi J, Yuan Y, Gu Y . Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma. Transl Oncol. 2020; 13(4):100758. PMC: 7097522. DOI: 10.1016/j.tranon.2020.100758. View

Gu W, Hu M, Wang W, Shi C, Mei J . Development and Validation of a Novel Nomogram for Predicting Tumor-Distant-Metastasis in Patients with Early T1-2 Stage Lung Adenocarcinoma. Ther Clin Risk Manag. 2020; 16:1213-1225. PMC: 7735943. DOI: 10.2147/TCRM.S272748. View

Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A . MGMT testing--the challenges for biomarker-based glioma treatment. Nat Rev Neurol. 2014; 10(7):372-85. DOI: 10.1038/nrneurol.2014.100. View

Van Meir E, Hadjipanayis C, Norden A, Shu H, Wen P, Olson J . Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010; 60(3):166-93. PMC: 2888474. DOI: 10.3322/caac.20069. View

Chelliah S, Paul E, Kamarudin M, Parhar I . Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas. Molecules. 2021; 26(4). PMC: 7927069. DOI: 10.3390/molecules26041169. View

Ludwig K, Kornblum H . Molecular markers in glioma. J Neurooncol. 2017; 134(3):505-512. PMC: 5568999. DOI: 10.1007/s11060-017-2379-y. View

Cai J, Yang P, Zhang C, Zhang W, Liu Y, Bao Z . ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples. Oncotarget. 2014; 5(9):2551-61. PMC: 4058026. DOI: 10.18632/oncotarget.1838. View

Aquilanti E, Wen P . Advanced molecular diagnostic tools: A step closer to precision medicine in neuro-oncology. Neuro Oncol. 2023; 25(10):1750-1751. PMC: 10547505. DOI: 10.1093/neuonc/noad132. View

Wu W, Deng Z, Alafate W, Wang Y, Xiang J, Zhu L . Preoperative Prediction Nomogram Based on Integrated Profiling for Glioblastoma Multiforme in Glioma Patients. Front Oncol. 2020; 10:1750. PMC: 7609958. DOI: 10.3389/fonc.2020.01750. View

10.

Zhang Z, Gu W, Hu M, Zhang G, Yu F, Xu J . Based on clinical Ki-67 expression and serum infiltrating lymphocytes related nomogram for predicting the diagnosis of glioma-grading. Front Oncol. 2022; 12:696037. PMC: 9488114. DOI: 10.3389/fonc.2022.696037. View

11.

Wang L, Liang S, Li C, Sun X, Pang L, Meng X . A Novel Nomogram and Risk Classification System Predicting Radiation Pneumonitis in Patients With Esophageal Cancer Receiving Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019; 105(5):1074-1085. DOI: 10.1016/j.ijrobp.2019.08.024. View

12.

Criniere E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A . MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol. 2007; 83(2):173-9. DOI: 10.1007/s11060-006-9320-0. View

13.

Clark O, Yen K, Mellinghoff I . Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. Clin Cancer Res. 2016; 22(8):1837-42. PMC: 4834266. DOI: 10.1158/1078-0432.CCR-13-1333. View

14.

Casartelli G, Dorcaratto A, Ravetti J, Sola S, Vitali A, Merlo D . Survival of high grade glioma patients depends on their age at diagnosis. Cancer Biol Ther. 2009; 8(18):1719-21. DOI: 10.4161/cbt.8.18.9209. View

15.

Tunthanathip T, Ratanalert S, Sae-Heng S, Oearsakul T, Sakarunchai I, Kaewborisutsakul A . Prognostic factors and clinical nomogram predicting survival in high-grade glioma. J Cancer Res Ther. 2021; 17(4):1052-1058. DOI: 10.4103/jcrt.JCRT_233_19. View

16.

van den Bent M, Dubbink H, Sanson M, van der Lee-Haarloo C, Hegi M, Jeuken J . MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009; 27(35):5881-6. PMC: 2793037. DOI: 10.1200/JCO.2009.24.1034. View

17.

Hegi M, Diserens A, Godard S, Dietrich P, Regli L, Ostermann S . Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004; 10(6):1871-4. DOI: 10.1158/1078-0432.ccr-03-0384. View

18.

Malmstrom A, Gronberg B, Marosi C, Stupp R, Frappaz D, Schultz H . Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012; 13(9):916-26. DOI: 10.1016/S1470-2045(12)70265-6. View

19.

Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. DOI: 10.1056/NEJMoa043331. View

20.

Zeng A, Hu Q, Liu Y, Wang Z, Cui X, Li R . IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma. Oncotarget. 2015; 6(30):30232-8. PMC: 4745793. DOI: 10.18632/oncotarget.4920. View